BACKGROUND: DNA microarray technology has enabled genomewide analysis of gene transcript levels, yielding insight into the molecular nature of liver disease. METHODS: We compared gene expression of liver biopsy specimens in 16 patients with different stages of chronic hepatitis B, five with autoimmune hepatitis (AIH), five with primary biliary cirrhosis (PBC), and six with druginduced hepatitis. RESULTS: Of 21 073 genes, 424 showed different expression in a particular disease group on analysis of variance. Genes associated with extracellular matrix, cell growth, and DNA repair were noted in the advanced fibrotic stage of chronic hepatitis B (B-3), while gene expression regarding complement activation and the innate immune response decreased. When we compared gene expression at the relatively early stage in each disease group with pathway analysis, pathways relating to chemotaxis and cell homeostasis were selected in chronic hepatitis B. In PBC, gene expression relating to structural constituents and contractions of muscle such as actin and myosin were enhanced, in contrast to the downregulation of genes relating to protein binding in AIH. A hierarchical clustering analysis of hepatitis B genes defined five clusters. Generally, the transcripts upregulated according to disease progression were associated with signaling pathway/transcription, including tumor-associated calcium signal transducer 1 and chemokine ligand 19, and with cell communication, such as collagen. In two groups, all transcripts were downregulated; transcripts related to chemokine ligands and metallothionein were further depressed in B-3. CONCLUSIONS: Analysis of gene expression in liver may be useful for understanding features of distinct liver diseases and for guiding disease progression, particularly in chronic hepatitis B.
BACKGROUND: DNA microarray technology has enabled genomewide analysis of gene transcript levels, yielding insight into the molecular nature of liver disease. METHODS: We compared gene expression of liver biopsy specimens in 16 patients with different stages of chronic hepatitis B, five with autoimmune hepatitis (AIH), five with primary biliary cirrhosis (PBC), and six with druginduced hepatitis. RESULTS: Of 21 073 genes, 424 showed different expression in a particular disease group on analysis of variance. Genes associated with extracellular matrix, cell growth, and DNA repair were noted in the advanced fibrotic stage of chronic hepatitis B (B-3), while gene expression regarding complement activation and the innate immune response decreased. When we compared gene expression at the relatively early stage in each disease group with pathway analysis, pathways relating to chemotaxis and cell homeostasis were selected in chronic hepatitis B. In PBC, gene expression relating to structural constituents and contractions of muscle such as actin and myosin were enhanced, in contrast to the downregulation of genes relating to protein binding in AIH. A hierarchical clustering analysis of hepatitis B genes defined five clusters. Generally, the transcripts upregulated according to disease progression were associated with signaling pathway/transcription, including tumor-associated calcium signal transducer 1 and chemokine ligand 19, and with cell communication, such as collagen. In two groups, all transcripts were downregulated; transcripts related to chemokine ligands and metallothionein were further depressed in B-3. CONCLUSIONS: Analysis of gene expression in liver may be useful for understanding features of distinct liver diseases and for guiding disease progression, particularly in chronic hepatitis B.
Authors: Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin Journal: Gastroenterology Date: 2005-12 Impact factor: 22.682
Authors: B J Murphy; G K Andrews; D Bittel; D J Discher; J McCue; C J Green; M Yanovsky; A Giaccia; R M Sutherland; K R Laderoute; K A Webster Journal: Cancer Res Date: 1999-03-15 Impact factor: 12.701
Authors: F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya Journal: J Hepatol Date: 1999-11 Impact factor: 25.083
Authors: H Okabe; S Satoh; T Kato; O Kitahara; R Yanagawa; Y Yamaoka; T Tsunoda; Y Furukawa; Y Nakamura Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki Journal: N Engl J Med Date: 1993-06-24 Impact factor: 91.245
Authors: Andrzej Cieśla; Maciej Kuśmider; Agata Faron-Górecka; Marta Dziedzicka-Wasylewska; Monika Bociąga-Jasik; Danuta Owczarek; Irena Ciećko-Michalska; Dorota Cibor; Tomasz Mach Journal: World J Gastroenterol Date: 2012-08-21 Impact factor: 5.742
Authors: Christopher L Bowlus; Erin H Seeley; Joanna Roder; Julia Grigorieva; Heinrich Roder; Richard M Caprioli; Meric Gershwin Journal: Cell Mol Immunol Date: 2011-01-24 Impact factor: 11.530